Drug intelligence / Profile preview

DNL628

Development stage: Phase 1
Lead developer: Denali Therapeutics
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intrathecal

Overview

DNL628 is an antisense oligonucleotide drug candidate developed by Denali Therapeutics for the treatment of Alzheimer's disease. It is designed to silence gene expression and inhibit tau protein expression, targeting the microtubule-associated protein tau (MAPT) gene. By reducing tau production, DNL628 aims to address neurodegeneration associated with abnormal tau accumulation in Alzheimer's disease. As of March 2024, it remains a new molecular entity in preclinical development[1][2][9].

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on DNL628.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNL628.

Explore the full profile